Trials Sponsors Conditions Drugs Pricing

Conditions

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

Keywords

Natural killer cellT cellLymphomaRadiationChemotherapy

Outcome Measures

Primary Outcomes (1)

Complete response
The response criteria was based on the International Working Group Report (1999).
Within 4 weeks after the completion of planned treatment

Secondary Outcomes (3)

Overall response rate
Up to 2 years
overall survival
up to 2 years
Progression-free survival
up to 2 years

Study Arms (1)

CCRT+MIDLE

EXPERIMENTAL

Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.

Radiation: CCRT+MIDLE chemotherapy

Interventions

CCRT+MIDLE chemotherapyRadiation

Patients are planned to be treated with CCRT plus MIDLE chemotherapy

Also known as: Chemoradiotherapy

CCRT+MIDLE

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

patients were required to have a biopsy-proven diagnosis of nasal ENKTL
at least 18 years old

Sponsors & Collaborators

Chonnam National University
Othercollaborator
Seoul National University
Othercollaborator
Samsung Medical Center

Study Sites (1)

Samsung Medical Center

Seoul, 135710, South Korea

MeSH Terms

Conditions

Lymphoma, Extranodal NK-T-CellLymphoma

Interventions

Chemoradiotherapy

Condition Hierarchy (Ancestors)

Lymphoma, T-CellLymphoma, Non-HodgkinNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Study Officials

Won Seog Kim, MD, PhD
Samsung Medical Center
PRINCIPAL INVESTIGATOR

Enrollment

30 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Associate professor

Study Record Dates

First Submitted

September 8, 2010

First Posted

November 10, 2010

Study Start

August 2010

Date type not reported

This date has not been verified as actual or estimated.

Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

CCRT+MIDLE

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Study Arms (1)

CCRT+MIDLE

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations